Professional profile
About James
James Whitfield advises pharmaceutical companies on regulatory compliance, advertising, global pharmacovigilance interfaces and China-Australia cross-border issues from Sydney.
Mr. Whitfield is admitted in New South Wales. He holds a law degree from an Australian university and has fifteen years of professional experience, working in English with bar credentials on file.
Read full profile
Pharmaceutical promotion is a recurring enforcement theme across markets. Claim language that works in English marketing often oversteps stricter standards elsewhere, including China.
Physicians may use products off-label. Manufacturers create a different problem when field force incentives effectively sell unapproved indications.
He reviews detailing aids, WeChat files and leave-behinds that exceed approved labels. Incentive schemes that reward indication share outside approved use are flagged. Silence after repeated off-label complaints from medical affairs is treated as ratification.
Version-controlled materials, mystery-shop style audits and rapid quarantine of rogue PDFs are the controls that survive inspection. Discipline files show the company does not ratify misconduct.
When an FDA Warning Letter names a China site, he coordinates global CAPA with PRC legal tracks and aligns public statements across markets.
Document holds on email and messaging begin when a dispute or regulatory inquiry is reasonably anticipated. Privilege-aware investigations preserve internal analysis while keeping safety reporting clocks moving.
Label decisions are documented in writing: update, watch or no action, with owners and dates. Silence in the file is what plaintiffs and inspectors read as delay.
Provide product type, promotional materials, label version history and any regulatory or inspection notice already received. Scope is confirmed in writing through this profile's inquiry channel.
Capability
